Next Article in Journal
Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?
Previous Article in Journal
Synchronous Metastatic Skull Base Chordoma to the Breast: Case Report and Literature Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 2
10.3747/co.23.2849
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?

by
Ibrahim Elghissassi
*,
Saber Boutayeb
,
Hanane Inrhaoun
,
Hind Mrabti
and
Hassan Errihani
Medical Oncology Department, National Institute of Oncology, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, AllalElfassi Street, Rabat 62000, Morocco
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(2), 158-159; https://doi.org/10.3747/co.23.2849
Submission received: 2 January 2016 / Revised: 3 February 2016 / Accepted: 5 March 2016 / Published: 1 April 2016

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We read with great interest the article of Ma and colleagues titled “An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre” [...]
Keywords: [N/A] [N/A]

Share and Cite

MDPI and ACS Style

Elghissassi, I.; Boutayeb, S.; Inrhaoun, H.; Mrabti, H.; Errihani, H. Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach? Curr. Oncol. 2016, 23, 158-159. https://doi.org/10.3747/co.23.2849

AMA Style

Elghissassi I, Boutayeb S, Inrhaoun H, Mrabti H, Errihani H. Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach? Current Oncology. 2016; 23(2):158-159. https://doi.org/10.3747/co.23.2849

Chicago/Turabian Style

Elghissassi, Ibrahim, Saber Boutayeb, Hanane Inrhaoun, Hind Mrabti, and Hassan Errihani. 2016. "Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?" Current Oncology 23, no. 2: 158-159. https://doi.org/10.3747/co.23.2849

APA Style

Elghissassi, I., Boutayeb, S., Inrhaoun, H., Mrabti, H., & Errihani, H. (2016). Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach? Current Oncology, 23(2), 158-159. https://doi.org/10.3747/co.23.2849

Article Metrics

Back to TopTop